Pharmaceuticals News & Analysis

REGN’s Eylea faces a rapid decline in sales, impacting overall performance even though Dupixent maintains momentum. We advise investors to stay on the sidelines for now.

Vertex Pharmaceuticals (VRTX) closed at $409.56 in the latest trading session, marking a -0.62% move from the prior day.

Marinus Pharmaceuticals (MRNS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

INCY vs. VRTX: Which Stock Is the Better Value Option?

The mean of analysts’ price targets for Recursion Pharmaceuticals (RXRX) points to a 28% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zentalis Pharmaceuticals (ZNTL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Catalyst stock gains 17% as it settles Firdapse patent litigation with Teva protecting the drug’s exclusivity in the United States till Feb. 25, 2035.

If approved, AGIO’s Pyrukynd will be the first oral therapy for all thalassemia subtypes. A final decision is expected by Sep. 7.

Amneal (AMRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

AbbVie (ABBV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.

Here, we discuss some reasons why investing in the VNDA stock now may turn out to be a prudent move.

NRXP, PDEX and PBYI made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 6, 2024.

Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Here is how ANI Pharmaceuticals (ANIP) and Adaptive Biotechnologies (ADPT) have performed compared to their sector so far this year.

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $402.70, marking a +0.84% move from the previous day.

Investors need to pay close attention to Vertex Pharmaceuticals (VRTX) stock based on the movements in the options market lately.

ANI (ANIP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company’s earnings prospects. This might drive the stock higher in the near term.

Tarsus Pharmaceuticals drew its inspiration from animal-health drugs. Now, the biotech stock is on a triple-digit run.
The post How Tarsus Pharmaceuticals' Unique Inspiration Is Driving A Triple-Digit Run appeared first on Investor's Business…

ADMA Biologics, Tarsus Pharmaceuticals, Stoke Therapeutics, Inc. and ChromaDex are part of the Zacks top Analyst Blog.

T-Mobile, Toyota Motor, Vertex Pharmaceuticals, BK Technologies and Servotronics are part of the Zacks top Analyst Blog.

NovaBay Pharmaceuticals (NBY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Here is how Alnylam Pharmaceuticals (ALNY) and argenex SE (ARGX) have performed compared to their sector so far this year.

In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $408.18, denoting a +0.72% change from the preceding trading day.

Today’s Research Daily features new research reports on 16 major stocks, including T-Mobile US, Inc. (TMUS), Toyota Motor Corporation (TM) and Vertex Pharmaceuticals Incorporated (VRTX), as well as two micro-cap stocks BK Technologies Corporation (BKTI) and Servotronics, Inc. (SVT).

The FDA’s nod is based on late-stage data, which show that treatment with VRTX’s Alyftrek enhances patient benefit compared to the blockbuster drug Trikafta.

Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.